Bleeding diathesis: Difference between revisions
No edit summary |
|||
Line 71: | Line 71: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Thrombin time (TT) | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Thrombin time (TT) | ||
|- | |- | ||
! rowspan="13" style="background: #4479BA; color: #FFFFFF; text-align: center;" |[[Platelet]] disorders | |||
! rowspan="7" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombocytopenia]] | |||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Infection]]-Induced [[thrombocytopenia]]<span name="harr_c115s002s001s002p001"></span><span name="9100754"></span><ref name="pmid21325604">{{cite journal |vauthors=Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA |title=The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia |journal=Blood |volume=117 |issue=16 |pages=4190–207 |date=April 2011 |pmid=21325604 |doi=10.1182/blood-2010-08-302984 |url=}}</ref><ref name="pmid26906627">{{cite journal |vauthors=Karimi O, Goorhuis A, Schinkel J, Codrington J, Vreden SGS, Vermaat JS, Stijnis C, Grobusch MP |title=Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus infection |journal=Lancet |volume=387 |issue=10022 |pages=939–940 |date=March 2016 |pmid=26906627 |doi=10.1016/S0140-6736(16)00502-X |url=}}</ref><ref name="pmid25600600">{{cite journal |vauthors=Zammarchi L, Stella G, Mantella A, Bartolozzi D, Tappe D, Günther S, Oestereich L, Cadar D, Muñoz-Fontela C, Bartoloni A, Schmidt-Chanasit J |title=Zika virus infections imported to Italy: clinical, immunological and virological findings, and public health implications |journal=J. Clin. Virol. |volume=63 |issue= |pages=32–5 |date=February 2015 |pmid=25600600 |doi=10.1016/j.jcv.2014.12.005 |url=}}</ref> | |||
| | | | ||
* History of prior infection | * History of prior infection | ||
Line 234: | Line 234: | ||
| - | | - | ||
|- | |- | ||
! rowspan="5" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Qualitative Disorders of [[Platelet]] Function<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span> | |||
! rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited Disorders of [[Platelet]] Function<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span> | |||
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Glanzmann's thrombasthenia|Glanzmann’s thrombasthenia]] | |||
| | | | ||
* Family history | * Family history | ||
Line 338: | Line 338: | ||
|See the table below for the details about types. | |See the table below for the details about types. | ||
|- | |- | ||
! rowspan="2" align="center" style="padding: 5px 5px; background: #4479BA;" |Vessel wall disorders | |||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Metabolism|Metabolic]] and [[Inflammation|Inflammatory]] Disorders | |||
! align="left" style="padding: 5px 5px; background: #DCDCDC;" | | |||
* Acute febrile illnesses | * Acute febrile illnesses | ||
* [[Cryoglobulinemia|Mixed cryoglobulinemia]] | * [[Cryoglobulinemia|Mixed cryoglobulinemia]] | ||
Line 386: | Line 386: | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|- | |- | ||
! rowspan="12" align="center" style="padding: 5px 5px; background: #4479BA;" |Coagulation factor disorders | |||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Fibrinogen]] deficiency | |||
! style="padding: 5px 5px; background: #DCDCDC;" |Different types of the [[fibrinogen]] disorders: | |||
* [[Fibrinogen#Congenital afibrinogenemia|Congenital afibrinogenemia]] | * [[Fibrinogen#Congenital afibrinogenemia|Congenital afibrinogenemia]] | ||
* [[Fibrinogen#Congenital hypofibrinogenemia|Congenital hypofibrinogenemia]] | * [[Fibrinogen#Congenital hypofibrinogenemia|Congenital hypofibrinogenemia]] | ||
Line 449: | Line 449: | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|- | |- | ||
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor V deficiency]] | |||
| | | | ||
* Excessive bruising with minor injuries | * Excessive bruising with minor injuries | ||
Line 470: | Line 470: | ||
|The severity of bleeding is only partly related to the degree of factor V deficiency. Some patients with undetectable plasma levels of factor V experience only relatively mild bleeding. | |The severity of bleeding is only partly related to the degree of factor V deficiency. Some patients with undetectable plasma levels of factor V experience only relatively mild bleeding. | ||
|- | |- | ||
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor VII deficiency]] | |||
| | | | ||
* Easy [[Bruise|bruising]] | * Easy [[Bruise|bruising]] | ||
Line 491: | Line 491: | ||
|Thrombosis occurs in inherited factor VII deficiency most cases are associated with the administration of factor VII replacement therapy | |Thrombosis occurs in inherited factor VII deficiency most cases are associated with the administration of factor VII replacement therapy | ||
|- | |- | ||
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor X deficiency]] | |||
| | | | ||
* Prolonged bleeding following circumcision | * Prolonged bleeding following circumcision | ||
Line 517: | Line 517: | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|- | |- | ||
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XII|Factor XII deficiency]] | |||
| | | | ||
* Majority,asymptomatic | * Majority,asymptomatic | ||
Line 535: | Line 535: | ||
| | | | ||
|- | |- | ||
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[High-molecular-weight kininogen|High molecular weight kininogen (HMWK)]] deficiency | |||
| | | | ||
* Possibility of positive family history of bleeding | * Possibility of positive family history of bleeding | ||
Line 551: | Line 551: | ||
| | | | ||
|- | |- | ||
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Prekallikrein]] deficiency | |||
| | | | ||
* Possibility of positive family history of bleeding | * Possibility of positive family history of bleeding | ||
Line 567: | Line 567: | ||
| | | | ||
|- | |- | ||
! colspan="2" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XIII deficiency]] | |||
| style="padding: 5px 5px; background: #DCDCDC;" |Types: | | style="padding: 5px 5px; background: #DCDCDC;" |Types: | ||
* Sub unit A mutation disease (more common) | * Sub unit A mutation disease (more common) | ||
Line 588: | Line 588: | ||
* The severity of factor XIII deficiency bleeds can be different in different patients | * The severity of factor XIII deficiency bleeds can be different in different patients | ||
|- | |- | ||
! rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemophilia]]<ref name="pmid94489952">{{cite journal |vauthors=Aviña-Zubieta JA, Galindo-Rodriguez G, Lavalle C |title=Rheumatic manifestations of hematologic disorders |journal=Curr Opin Rheumatol |volume=10 |issue=1 |pages=86–90 |date=January 1998 |pmid=9448995 |doi= |url=}}</ref><ref name="pmid16551972">{{cite journal |vauthors=Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AH, van Amstel HK, van der Bom JG, van Diemen-Homan JE, Willemse J, Rosendaal FR |title=Bleeding in carriers of hemophilia |journal=Blood |volume=108 |issue=1 |pages=52–6 |date=July 2006 |pmid=16551972 |doi=10.1182/blood-2005-09-3879 |url=}}</ref><ref name="pmid25059285">{{cite journal |vauthors=Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A |title=Definitions in hemophilia: communication from the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=12 |issue=11 |pages=1935–9 |date=November 2014 |pmid=25059285 |doi=10.1111/jth.12672 |url=}}</ref><ref name="pmid11307831">{{cite journal |vauthors=White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J |title=Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis |journal=Thromb. Haemost. |volume=85 |issue=3 |pages=560 |date=March 2001 |pmid=11307831 |doi= |url=}}</ref><ref name="pmid24026910">{{cite journal |vauthors=Favaloro EJ, Meijer P, Jennings I, Sioufi J, Bonar RA, Kitchen DP, Kershaw G, Lippi G |title=Problems and solutions in laboratory testing for hemophilia |journal=Semin. Thromb. Hemost. |volume=39 |issue=7 |pages=816–33 |date=October 2013 |pmid=24026910 |doi=10.1055/s-0033-1356573 |url=}}</ref><ref name="pmid250592852">{{cite journal |vauthors=Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A |title=Definitions in hemophilia: communication from the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=12 |issue=11 |pages=1935–9 |date=November 2014 |pmid=25059285 |doi=10.1111/jth.12672 |url=}}</ref> | |||
| colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type A deficiency | | colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type A deficiency | ||
Line 647: | Line 647: | ||
| - | | - | ||
|- | |- | ||
! rowspan="2" align="center" style="padding: 5px 5px; background: #4479BA;" |Rare diseases | |||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]] | |||
! style="padding: 5px 5px; background: #DCDCDC;" | | |||
* [[Trauma]] | * [[Trauma]] | ||
* Burn | * Burn | ||
Line 670: | Line 670: | ||
| - | | - | ||
|- | |- | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Vitamin K Deficiency]] | |||
! style="padding: 5px 5px; background: #DCDCDC;" | | |||
* Bleeding after trauma | * Bleeding after trauma | ||
* [[Epistaxis]] | * [[Epistaxis]] |
Revision as of 21:59, 1 October 2018
Bleeding diathesis main page |
|
---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2], Nazia Fuad M.D.
Overview
Bleeding diathesis is susceptibility to bleed due to coagulopathy disorders or platelets disorders. These diseases can occur due to a disorder of homeostasis, localized process (tissue injury), or medications. Bleeding diathesis can be resulted from vessel wall injury, platelet disorders, and coagulation factor disorders. Clinical manifestation of bleeding disorders can have a wide range of symptoms from asymptomatic to symptomatic massive and life threatening bleeding. Platelet disorders mostly have skin manifestations such as petechiae, and ecchymoses. In order to find the cause of hypo-coagulopathy; there are established laboratory tests, such as peripheral blood smear, platelet count and platelet function analysis, coagulation factor deficiencies and inhibitors, fibrinolysis tests (eg. D-dimer level), bleeding time (BT), prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT), and reptilase time. In the case of any abnormal bleeding, first line of screening tests are CBC, PT, PTT, BT, and TT.[1]
Classification
Disorders of hemostasis can be classified into two main categories: platelet disorders, and disorders of coagulation. Each category can be further classified as bellow:
Platelet disorders:
- Thrombocytopenia: platelet count less than 150,000 per mm3
- Thromobcytosis: platelet count more than 450,000 per mm3
- Qualitative Disorders of Platelet function such as Von Willebrand Disease, inherited or acquired functional disorders.
Coagulation disorders
- Vessel wall disorders: Endothelial cells are lining entire vessel walls all over the body. Endothelium is an active layer responsible for inflammatory responses, angiogenesis and blood cell interactions. Endothelial cells have a very important role in hemostasis and they are regulating blood fluidity by the balance of antithrombotic/prothrombotic and vasodilatory/vasoconstrictor effects.
- Metabolic and Inflammatory Disorders
- Inherited Disorders of the Vessel Wall
- Coagulation factor disorders:
- Fibrinogen deficiency
- Prothrombin deficiency
- Factor V deficiency
- Factor VII deficiency
- Factor X deficiency
- Factor XII deficiency
- HK deficiency
- Prekallikrein deficiency
- Factor XIII deficiency
- Hemophilia
- Disseminated Intravascular Coagulation
- Vitamin K Deficiency
- Coagulation Disorders Associated with Liver Failure
- Acquired Inhibitors of Coagulation Factors
Abnormal hematosis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
•Patient history-sign & symptom: Deep soft tissue bleeding Mucocutaneus bleeding •Screen test CBBC-plt-PT&PTT-BT-TT | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hx of deep soft tissue bleeding | Hx of mucocotaneus bleeding | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Coagulopathy | Plt disorder | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Family history | Normal plt count | Low plt count | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Differential Diagnosis
Differential diagnosis of "Bleeding disorders":
Category | Sub-category | Diseases | History | Clinical manifestation | Laboratory testing | Comments | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mucosal bleeding | Petechia|Petechiae | Ecchymoses | Menorrhagia | Hematoma | Hemarthrosis | Platelet count | Bleeding time (BT) | Prothrombin time (PT) | Activated partial thromboplastin time (aPTT) | Thrombin time (TT) | ||||||
Platelet disorders | Thrombocytopenia | Infection-Induced thrombocytopenia[2][3][4] |
|
+ | + | + | + | + | + | ↓ | ↑ | Normal | Normal | Normal | - | |
Medications-Induced thrombocytopenia [5][6] |
|
+ | + | + | + | + | + | ↓ | ↑ | Normal | Normal | Normal | Most important par of treatment is discontinuing of the medication. | |||
Heparin-Induced thrombocytopenia[7] |
|
+ | + | + | + | + | + | ↓ | ↑ | Normal | Normal | ↑ | For more information click here: Heparin-induced thrombocytopenia. | |||
Immune Thrombocytopenic Purpura (ITP)[8] |
|
+ | + | + | + | + | + | ↓ | ↑ | Normal | Normal | Normal | - | |||
Inherited Thrombocytopenia[9][10] |
|
+ | + | + | + | + | + | ↓ | ↑ | Normal | Normal | Normal | - | |||
Thrombotic Thrombocytopenic Purpura (TTP)[11][12] | History of:
|
+ | + | + | + | + | + | ↓ | ↑ | Normal | Normal | Normal | - | |||
Hemolytic Uremic Syndrome[13][14] | History of:
|
+ | + | + | + | + | + | ↓ | ↑ | Normal | Normal | Normal | - | |||
Thromobcytosis | Iron deficiency anemia
Inflammatory diseases |
|
- | − | − | − | +/- | +/- | ↑ | Normal/↑ | Normal | Normal | Normal | - | ||
Qualitative Disorders of Platelet Function | Inherited Disorders of Platelet Function | Glanzmann’s thrombasthenia |
|
+ | + | + | + | - | Rare | Normal/↓ | ↑ | Normal | Normal | Normal |
| |
Bernard-Soulier syndrome[15][16] |
|
+ | + | + | + | - | - | Normal/↓ | ↑ | Normal | Normal | Normal |
| |||
Platelet storage pool disorder (SPD): |
|
+ | + | + | + | - | - | Normal/↓ | ↑ | Normal | Normal | Normal |
| |||
Acquired Disorders of Platelet Function |
|
+ | + | + | + | +/- | +/- | Normal/↓ | ↑ | Normal | Normal | Normal | - | |||
Von Willebrand Disease [17][17][18][19][20] |
|
+ | + | + | + | +/- | +/- | ↑ | Normal | ↑ | ↑ | Normal | See the table below for the details about types. | |||
Vessel wall disorders | Metabolic and Inflammatory Disorders |
|
|
- | + | + | +/- | - | - | Normal | ↑/Normal | Normal | Normal | Normal | - | |
Inherited Disorders of the Vessel Wall |
|
- | + | + | +/- | - | - | Normal | ↑/Normal | Normal | Normal | Normal | - | |||
Coagulation factor disorders | Fibrinogen deficiency | Different types of the fibrinogen disorders: |
|
- | - | + | + | +/- | + | Normal | ↑ | ↑ | ↑ | ↑ |
| |
Prothrombin deficiency |
|
+ | + | + | + | + | Normal | Normal | ↑ | ↑ | ↑ | - | ||||
Factor V deficiency |
|
_ | + | + | + | + | Normal | ↑ | ↑ | ↑ | Normal | The severity of bleeding is only partly related to the degree of factor V deficiency. Some patients with undetectable plasma levels of factor V experience only relatively mild bleeding. | ||||
Factor VII deficiency |
|
+ | + | + | Normal | ↑ | Normal | Normal | Thrombosis occurs in inherited factor VII deficiency most cases are associated with the administration of factor VII replacement therapy | |||||||
Factor X deficiency |
|
+ | + | + | + | + | Normal | Normal | ↑ | ↑ | Normal | - | ||||
Factor XII deficiency |
|
_ | _ | _ | _ | _ | Normal | Normal | Normal | ↑ | Normal | |||||
High molecular weight kininogen (HMWK) deficiency |
|
_ | _ | _ | _ | _ | Normal | Normal | Normal | ↑ | Normal | |||||
Prekallikrein deficiency |
|
_ | _ | _ | _ | _ | Normal | Normal | Normal | ↑ | Normal | |||||
Factor XIII deficiency | Types:
|
|
-/+ | -/+ | -/+ | -/+ | -/+ | -/+ | Normal | Normal | Normal/↑ | Normal | Normal |
| ||
Hemophilia[21][22][23][24][25][26] | Type A deficiency |
|
- | - | - | + | + | + | Normal | Normal | Normal | ↑ | Normal | - | ||
Type B deficiency |
|
- | - | - | + | + | + | Normal | Normal | Normal | ↑ | Normal | - | |||
Type C deficiency |
|
- | - | - | + | Rare | Rare | Normal | Normal | Normal | ↑ | Normal | - | |||
Rare diseases | Disseminated Intravascular Coagulation |
|
+ | + | + | + | + | + | ↓ | ↑ | ↑ | ↑ | Normal | - | ||
Vitamin K Deficiency |
|
+ | - | + | + | + | + | Normal | ↑ | ↑ | Normal or mildly prolonged | Normal | - |
Type of VWD | Type of factor deficiency | Prevalence | Inheritance pattern | Clinical manifestations | VWF activity | RIPA | Factor VIII | |
---|---|---|---|---|---|---|---|---|
Type 1 | Quantitative/ partial | 60-70% | AD |
|
↓ | ↓ | ↓ | |
Type 2 | 2A[28] | Qualitative | 10% | AD/AR |
|
↓ | ↓ | N or ↓ |
2B | Qualitative | 5% | AD |
|
↓ | ↑ | N or↓ | |
2M | Qualitative | <1% | AD/AR |
|
↓ | ↓ | N or ↓ | |
2N | Qualitative | <1% | AR |
|
N | N | ↓ | |
Type 3 | Complete deficiency | 1-2% | AR |
|
Absent | ↓ |
Low, 1-10% |
For more information on Von Willebrand disease click here
References
- ↑ Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL (September 2003). "Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice". Thromb. Haemost. 90 (3): 483–90. doi:10.1160/TH03-02-0111. PMID 12958618.
- ↑ Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA (April 2011). "The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia". Blood. 117 (16): 4190–207. doi:10.1182/blood-2010-08-302984. PMID 21325604.
- ↑ Karimi O, Goorhuis A, Schinkel J, Codrington J, Vreden S, Vermaat JS, Stijnis C, Grobusch MP (March 2016). "Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus infection". Lancet. 387 (10022): 939–940. doi:10.1016/S0140-6736(16)00502-X. PMID 26906627. Vancouver style error: initials (help)
- ↑ Zammarchi L, Stella G, Mantella A, Bartolozzi D, Tappe D, Günther S, Oestereich L, Cadar D, Muñoz-Fontela C, Bartoloni A, Schmidt-Chanasit J (February 2015). "Zika virus infections imported to Italy: clinical, immunological and virological findings, and public health implications". J. Clin. Virol. 63: 32–5. doi:10.1016/j.jcv.2014.12.005. PMID 25600600.
- ↑ Kam T, Alexander M (October 2014). "Drug-induced immune thrombocytopenia". J Pharm Pract. 27 (5): 430–9. doi:10.1177/0897190014546099. PMID 25134884.
- ↑ Seco-Melantuche R, Delgado-Sánchez O, Álvarez-Arroyo L (2013). "[Incidence of drug-induced thrombocytopenia in hospitalized patients]". Farm Hosp (in Spanish; Castilian). 37 (1): 27–34. doi:10.7399/FH.2013.37.1.42. PMID 23461497.
- ↑ Warkentin TE, Safyan EL, Linkins LA (January 2015). "Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages". N. Engl. J. Med. 372 (5): 492–4. doi:10.1056/NEJMc1414161. PMID 25629757.
- ↑ Wright JF, Blanchette VS, Wang H, Arya N, Petric M, Semple JW, Chia WK, Freedman J (October 1996). "Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP)". Br. J. Haematol. 95 (1): 145–52. PMID 8857953.
- ↑ Johnson B, Fletcher SJ, Morgan NV (September 2016). "Inherited thrombocytopenia: novel insights into megakaryocyte maturation, proplatelet formation and platelet lifespan". Platelets. 27 (6): 519–25. doi:10.3109/09537104.2016.1148806. PMC 5000870. PMID 27025194.
- ↑ Wang Q, Cao L, Sheng G, Shen H, Ling J, Xie J, Ma Z, Yin J, Wang Z, Yu Z, Chen S, Zhao Y, Ruan C, Xia L, Jiang M (August 2018). "Application of High-Throughput Sequencing in the Diagnosis of Inherited Thrombocytopenia". Clin. Appl. Thromb. Hemost.: 1076029618790696. doi:10.1177/1076029618790696. PMID 30103613.
- ↑ Knöbl P (2018). "Thrombotic thrombocytopenic purpura". Memo. 11 (3): 220–226. doi:10.1007/s12254-018-0429-6. PMID 30220931.
- ↑ Mannucci PM, Cugno M (November 2015). "The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring". Thromb. Res. 136 (5): 851–4. doi:10.1016/j.thromres.2015.09.007. PMID 26386489.
- ↑ Webster K, Schnitzler E (2014). "Hemolytic uremic syndrome". Handb Clin Neurol. 120: 1113–23. doi:10.1016/B978-0-7020-4087-0.00075-9. PMID 24365375.
- ↑ Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P (June 2015). "Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome". Pathol. Biol. 63 (3): 136–43. doi:10.1016/j.patbio.2015.03.001. PMID 25845294.
- ↑ Dupuis A, Gachet C (September 2018). "Inherited platelet disorders : Management of the bleeding risk". Transfus Clin Biol. 25 (3): 228–235. doi:10.1016/j.tracli.2018.07.003. PMID 30077511.
- ↑ Andres O, Henning K, Strauß G, Pflug A, Manukjan G, Schulze H (June 2018). "Diagnosis of platelet function disorders: A standardized, rational, and modular flow cytometric approach". Platelets. 29 (4): 347–356. doi:10.1080/09537104.2017.1386297. PMID 29227167.
- ↑ 17.0 17.1 Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, Hopman W, Clark DS, Mauer AC, Bowman M, Riddel J, Christopherson PA, Montgomery RR, Rand ML, Coller B, James PD (November 2014). "Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project". Haemophilia. 20 (6): 831–5. doi:10.1111/hae.12503. PMC 4251588. PMID 25196510.
- ↑ Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, Hallden C, Guilliatt A, Lester W, Peake I (January 2007). "Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)". Blood. 109 (1): 112–21. doi:10.1182/blood-2006-05-020784. PMID 16985174.
- ↑ Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ (1998). "PFA-100 system: a new method for assessment of platelet dysfunction". Semin. Thromb. Hemost. 24 (2): 195–202. doi:10.1055/s-2007-995840. PMID 9579642.
- ↑ Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J (July 2015). "Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH". J. Thromb. Haemost. 13 (7): 1345–50. doi:10.1111/jth.12964. PMC 5576173. PMID 25858564.
- ↑ Aviña-Zubieta JA, Galindo-Rodriguez G, Lavalle C (January 1998). "Rheumatic manifestations of hematologic disorders". Curr Opin Rheumatol. 10 (1): 86–90. PMID 9448995.
- ↑ Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AH, van Amstel HK, van der Bom JG, van Diemen-Homan JE, Willemse J, Rosendaal FR (July 2006). "Bleeding in carriers of hemophilia". Blood. 108 (1): 52–6. doi:10.1182/blood-2005-09-3879. PMID 16551972.
- ↑ Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A (November 2014). "Definitions in hemophilia: communication from the SSC of the ISTH". J. Thromb. Haemost. 12 (11): 1935–9. doi:10.1111/jth.12672. PMID 25059285.
- ↑ White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J (March 2001). "Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis". Thromb. Haemost. 85 (3): 560. PMID 11307831.
- ↑ Favaloro EJ, Meijer P, Jennings I, Sioufi J, Bonar RA, Kitchen DP, Kershaw G, Lippi G (October 2013). "Problems and solutions in laboratory testing for hemophilia". Semin. Thromb. Hemost. 39 (7): 816–33. doi:10.1055/s-0033-1356573. PMID 24026910.
- ↑ Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A (November 2014). "Definitions in hemophilia: communication from the SSC of the ISTH". J. Thromb. Haemost. 12 (11): 1935–9. doi:10.1111/jth.12672. PMID 25059285.
- ↑ Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J (July 2015). "Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH". J. Thromb. Haemost. 13 (7): 1345–50. doi:10.1111/jth.12964. PMC 5576173. PMID 25858564.
- ↑ Lyons SE, Bruck ME, Bowie EJ, Ginsburg D (March 1992). "Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations". J. Biol. Chem. 267 (7): 4424–30. PMID 1537829.